Parkinson's disease, Ozempic
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.
Daniel Barenboim, Parkinson's disease
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Sharon Osbourne gave an update on how Parkinson’s disease has impacted husband Ozzy Osbourne’s legs as the musician prepares ...
Osbourne is set to reunite with original bandmates Tony Iommi, Geezer Butler and Bill Ward for a farewell concert in July.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback